Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming ...
Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that ...
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...
Culver City-based ImmunityBio, Inc., a leading immunotherapy company, has announced that the U.S. Food and Drug ...
The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...
Neoadjuvant disitamab vedotin plus perioperative toripalimab showed promising efficacy and acceptable safety in patients with HER2-expressing MIBC, according to Xinan Sheng, MD.
Q4 2024 Earnings Call Transcript March 4, 2025 Compugen Ltd. misses on earnings expectations. Reported EPS is $-0.07 EPS, ...
Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25- Interim datasets from GALAXIES H&N-202 and ...
The researchers found that factors favoring chemoimmunotherapy included higher socioeconomic status, being uninsured, a more ...
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...